---
title: Controversies in orthopaedic oncology
date: '2024-05-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38689572/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240501181354&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Chondrosarcoma is the second most common surgically treated primary bone
  sarcoma. Despite a large number of scientific papers in the literature, there is
  still significant controversy about diagnostics, treatment of the primary tumour,
  subtypes, and complications. Therefore, consensus on its day-to-day treatment decisions
  is needed. In January 2024, the Birmingham Orthopaedic Oncology Meeting (BOOM) attempted
  to gain global consensus from 300 delegates from over 50 countries. The meeting
  ...
disable_comments: true
---
Chondrosarcoma is the second most common surgically treated primary bone sarcoma. Despite a large number of scientific papers in the literature, there is still significant controversy about diagnostics, treatment of the primary tumour, subtypes, and complications. Therefore, consensus on its day-to-day treatment decisions is needed. In January 2024, the Birmingham Orthopaedic Oncology Meeting (BOOM) attempted to gain global consensus from 300 delegates from over 50 countries. The meeting ...